Epigenetic analysis of Paget's disease of bone identifies differentially methylated loci that predict disease status

  1. Ilhame Diboun
  2. Sachin Wani
  3. Stuart H Ralston
  4. Omar M E Albagha  Is a corresponding author
  1. Hamad Bin Khalifa University, Qatar
  2. University of Edinburgh, United Kingdom

Abstract

Paget's Disease of Bone (PDB) is characterized by focal increases in disorganized bone remodeling. This study aims to characterize PDB associated changes in DNA methylation profiles in patients' blood. Meta-analysis of data from the discovery and cross-validation set, each comprising of 116 PDB cases and 130 controls, revealed significant differences in DNA methylation at 14 CpG sites, 4 CpG islands, and 6 gene-body regions. These loci, including two characterized as functional through expression quantitative trait-methylation (eQTM) analysis, were associated with functions related to osteoclast differentiation, mechanical loading, immune function, and viral infection. A multivariate classifier based on discovery samples was found to discriminate PDB cases and controls from the cross-validation with a sensitivity of 0.84, specificity of 0.81, and an area under curve of 92.8%. In conclusion, this study has shown for the first time that epigenetic factors contribute to the pathogenesis of PDB and may offer diagnostic markers for prediction of the disease.

Data availability

Raw and processed methylation data generated in this study can be found at GEO under the accession GSE163970.

The following data sets were generated

Article and author information

Author details

  1. Ilhame Diboun

    College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
    Competing interests
    No competing interests declared.
  2. Sachin Wani

    Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    No competing interests declared.
  3. Stuart H Ralston

    Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    Stuart H Ralston, Prof S H Ralston has received research funding from Amgen, Eli Lilly, Novartis, and Pfizerunrelated to the submitted work. The author has no other competing interests to declare..
  4. Omar M E Albagha

    College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
    For correspondence
    oalbagha@hbku.edu.qa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5916-5983

Funding

European Research Council (FP7/2007-2013)

  • Omar M E Albagha

European Research Council (787270-Paget-Advance)

  • Stuart H Ralston

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the UK Multicenter Research Ethics Committee for Scotland(MREC01/0/53) and NHS Lothian, Edinburgh (08/S1104/8) ethics review committees. Allparticipants provided written informed consent.

Copyright

© 2021, Diboun et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 833
    views
  • 126
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ilhame Diboun
  2. Sachin Wani
  3. Stuart H Ralston
  4. Omar M E Albagha
(2021)
Epigenetic analysis of Paget's disease of bone identifies differentially methylated loci that predict disease status
eLife 10:e65715.
https://doi.org/10.7554/eLife.65715

Share this article

https://doi.org/10.7554/eLife.65715

Further reading

    1. Chromosomes and Gene Expression
    2. Computational and Systems Biology
    Miguel Martinez-Ara, Federico Comoglio, Bas van Steensel
    Research Article

    Genes are often regulated by multiple enhancers. It is poorly understood how the individual enhancer activities are combined to control promoter activity. Anecdotal evidence has shown that enhancers can combine sub-additively, additively, synergistically, or redundantly. However, it is not clear which of these modes are more frequent in mammalian genomes. Here, we systematically tested how pairs of enhancers activate promoters using a three-way combinatorial reporter assay in mouse embryonic stem cells. By assaying about 69,000 enhancer-enhancer-promoter combinations we found that enhancer pairs generally combine near-additively. This behaviour was conserved across seven developmental promoters tested. Surprisingly, these promoters scale the enhancer signals in a non-linear manner that depends on promoter strength. A housekeeping promoter showed an overall different response to enhancer pairs, and a smaller dynamic range. Thus, our data indicate that enhancers mostly act additively, but promoters transform their collective effect non-linearly.

    1. Chromosomes and Gene Expression
    2. Medicine
    Xianghong Xie, Mingyue Gao ... Xiaojun Liu
    Research Article

    LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Pparg promoter and enhancing PPARγ expression. The administration of PPARγ antagonist T0070907 improved Snhg3-aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3/SND1/H3K27me3/PPARγ, responsible for mice MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.